A Game Changing Technology Creates a New Class of Preemptive and Proactive Molecular Tests
[SEOUL, SOUTH KOREA & GAITHERSBURG, MD=Whowired] May 31, 2012- Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex molecular diagnostic technologies and tests, today announced the development of a new molecular technology that for the first time allows high multiplexing and multiple quantification from a single sample in a single tube.
Seegene's real-time multiplex PCR technology allows the simultaneous detection and quantification of up to 20 analytes on an existing 4-channel real-time instrument. This technology can provide life science companies with a competitive edge in a wide range of molecular testing applications and industry sectors. Seegene intends to make the technology broadly available to the life science market on a co-development or out-license basis.
"This represents a new class of molecular diagnostics (MoDx) technology that for the first time delivers highly multiplexed quantitative tests that can be run on potentially any real-time instrument. Using this new technology as their core MoDx technology, a wide variety of life science firms can develop comprehensive multiplexed diagnostic tests that can both detect and quantify all possible analytes in a single tube," said Dr. Jong-Yoon Chun, founder, CTO and CEO of Seegene.
"By enabling the quantification of multiple targets, the technology opens vast new and previously unimagined possibilities for new molecular tests. Opening this technology to a wide spectrum of companies operating in diverse markets is a game changer in molecular testing, and will promote a paradigm shift to well-conceived, intuitive tests that can be utilized in a preemptive or proactive manner," added Dr. Chun.
Seegene will introduce the first assay based on the technology at the 2012 AACC Annual Meeting (July 15-19, Los Angeles): A highly multiplexed assay that will detect, differentiate and quantitate 19 high risk and 9 low risk Human Papilloma Virus genotypes.
Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies -- ACP™, DPO™, READ, and TOCE™ -- are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.
For more information please visit www.seegene.com or call +301-762-9066.
David L. Dolinger, Ph.D.
|Groupon Announces Acquisition of Korea’s Ticket Monster|
|Partial Pulpotomy using Maruchi Product Recognized a New Health Technology by the Ministry of Health – Health Insurance Benefit Expected|
|Daeyang Medical Develops a Beauty Treatment Device Decell|
|KIA MOTORS AMERICA ELECTRIFIES LAS VEGAS WITH MUSIC-DRIVEN SOULS AT SEMA|
|Hyundai Announces New Crate Engine Program for 3.8-liter V6 and 2.0-liter Turbo Engines at 2013 SEMA Show|
|Integral Technologies Reports Further Progress in Strategic Alliance with Hanwha L&C|
|'Global Partnership Korea 2013 & IMAC 2013' Kicked off!|
|Samsung Answers Mystery Surrounding #WinnerTakesEarth|
|Rehabilitation Equipment Maker Promedi Signs the ISO 13485 and CE Mark Certification Agreement for Oversea Expansion|
|Medical Training Simulator Company BT Well Received at APMSH 2013 in China|
|Samsung Electronics Launches Business Core™ Printing Solutions for SMBs|
|Seoul TouchUp Now Expands Its Business to the Heart of Korean Plastic Surgery|